二甲双胍诱导维生素B12缺乏的遗传风险因子鉴定
研究在UK Biobank中识别并验证了CUBN基因rs1801222位点与二甲双胍诱导的维生素B12缺乏的关联,该关联在苏格兰队列和DPPOS中重复验证。携带AA基因型者使用二甲双胍时维生素B12缺乏风险显著增高,提示可针对高危基因型进行靶向监测。
要点
- CUBN基因rs1801222位点与二甲双胍诱导的维生素B12缺乏显著相关
- AA基因型者使用二甲双胍时维生素B12缺乏风险最高
- 建议对携带高风险基因型的二甲双胍使用者进行靶向B12监测
核心结论
- rs1801222基因型应被视为二甲双胍诱导维生素B12缺乏的重要风险因素。
- 该发现提示对遗传高风险人群进行靶向监测具有潜在临床价值。
研究设计与样本
- 在UK Biobank中识别487例二甲双胍诱导维生素B12缺乏者和6686例二甲双胍耐受对照者。
- 采用逻辑回归进行全基因组关联分析,并在苏格兰队列、DPPOS和利物浦队列中进行重复验证。
- 利物浦队列中额外测量了血浆二甲双胍水平。
主要发现
- CUBN基因rs1801222/p.S253F非同义SNP与二甲双胍诱导的维生素B12缺乏全基因组显著相关(加性模型;校正p=1.86×10-10;AG vs GG的OR 1.56 [95% CI 1.36, 1.79];AA vs GG的OR 2.43 [95% CI 1.85, 3.20])。
- 该关联在苏格兰队列和DPPOS队列中均得到重复验证。
- 非二甲双胍暴露个体中维生素B12缺乏发生率为0.84-1.20%,与rs1801222基因型无关。
- 与二甲双胍使用存在显著交互作用:维生素B12缺乏发生率在GG组为6.02%、GA组为7.96%、AA组为12.84%。
- 从二甲双胍起始随访,AA基因型者10%在11年时出现维生素B12缺乏,而GG基因型者10%需21年。
临床怎么用
- 对携带CUBN rs1801222高风险基因型(尤其是AA型)的二甲双胍使用者,可考虑更早或更频繁地监测血清维生素B12水平。
- 目前二甲双胍使用者血清维生素B12监测执行不一致,该发现支持对遗传高危亚组实施靶向监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: Metformin, a mainstay of treatment for type 2 diabetes, can cause vitamin B12 deficiency. Clinical risk factors have been identified but genetic factors remain undiscovered. Our objective was to identify and validate genetic predisposing factors and establish clinical utility. METHODS: Individuals with metformin-induced vitamin B12 deficiency (n=487) and metformin-tolerant control individuals (n=6686) were identified in UK Biobank. Genome-wide association analysis was undertaken using logistic regression. Replication was undertaken in three cohorts: a Scottish cohort; the Diabetes Prevention Program Outcomes Study (DPPOS); and a separate cohort from Liverpool. In the Liverpool cohort, plasma metformin levels were also measured. RESULTS: Analysis identified a genome-wide significant non-synonymous SNP in the cubilin gene (CUBN, rs1801222/p.S253F) associated with metformin-induced vitamin B12 deficiency (additive model; adjusted p=1.86×10-10; OR 1.56 [95% CI 1.36, 1.79] for AG vs GG genotype; OR 2.43 [95% CI 1.85, 3.20] for AA vs GG genotype), which was replicated in both the Scottish and the DPPOS cohorts. Vitamin B12 deficiency occurred in 0.84-1.20% of non-metformin-exposed individuals regardless of rs1801222 genotype. However, a large interaction with metformin use was observed, with vitamin B12 deficiency occurring at 6.02% in GG, 7.96% in GA and 12.84% in AA genotype groups. When followed up from metformin initiation, 10% with the AA genotype were vitamin B12 deficient by 11 years vs 21 years for 10% of the GG group. CONCLUSIONS/INTERPRETATION: The observed genetic association suggests that the rs180122 genotype should be considered a significant risk factor for metformin-induced vitamin B12 deficiency. While clinical monitoring of serum vitamin B12 levels in patients on metformin is inconsistently done, this finding highlights the potential clinical utility of targeted monitoring for certain subsets of individuals, including those genetically at high risk.
引用
- Baldwin FD, Bedair KF, Jorgensen AL, et al. Identification of a genetic risk factor for metformin-induced vitamin B12 deficiency. Diabetologia. 2026. PMID: 41537778. doi:10.1007/s00125-025-06655-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。